脊椎関節炎治療薬の世界市場機会分析...市場調査レポートについてご紹介

【英文タイトル】OpportunityAnalyzer: Axial Spondyloarthritis - Opportunity Analysis and Forecast to 2024 - Event-Driven Update

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼
脊椎関節炎治療薬の世界市場機会分析 (Code:GDHC012EPOA)

【レポートの概要(一部)】

OpportunityAnalyzer: Axial Spondyloarthritis – Opportunity Analysis and Forecast to 2024 – Event-Driven Update

Summary

Ankylosing Spondylitis (AS) is an autoimmune disease that causes inflammation of the sacroiliac joint accompanied by pain and stiffness of the lower back, which typically gets better with exercise. Ankylosis (fusion) of the spine is typically a late-stage complication and has been nicknamed “bamboo spine”, due to its appearance on X-ray. It is now recognized that the pathological changes leading to ankylosis develop over time, and an early stage of the disease, known as non-radiographic axial spondyloarthritis (nr-axSpA) is characterized by the same symptoms of inflammatory back pain without radiographic changes observed by X-ray. Together, AS and nr-axSpA are known as axial spondyloarthritis (axSpA). AS and nr-axSpA affect roughly 1.3 million and 700,000 individuals, respectively, in the seven major pharmaceutical markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan) covered in this report and the prevalence is expected to grow mainly due to changes in diagnosis rates. The anti-TNFs have been effective in treating the signs and symptoms of axSpA, however, there is a lack of effective therapeutic classes, and no treatment options for patients who have failed anti-TNF therapy, representing a key unmet need and opportunities for drug developers.

Highlights

Key Questions Answered

– What are the preferred anti-TNFs for and how will competition from pipeline agents and biosimilars affect sales? Are rheumatologists across the 7MM expected to prescribe biosimlars for axSpA?
– Will there be strong uptake of pipeline agents and how will Novartis’s Cosentyx, J&J’s Stelara, and Celgene’s Otezla be used in the clinic?
– According to key opinion leaders (KOLs), what are the most important unmet needs in axSpA? Will these needs be addressed by pipeline agents? What needs will remain by the end of the forecast period in 2024?
– How will disease awareness change over the forecast period and will this affect diagnosis?
– How is non-radiographic axial spondyloarthritis (nr-axSpA) treated and will the diagnosis and treatment change over the next decade? Which drugs are expected to gain label expansions into nr-axSpA?

Key Findings

– Increased diagnosis and treatment are key drivers in the axSpA market.
– Novartis’s Cosentyx and J&J’s Stelara will address the unmet need for drugs with novel MOAs and pose a threat to anti-TNFs, which are currently the only therapeutic class beyond NSAIDs.
– Label expansions into AS and nr-axSpA are expected to be an increasingly popular life-cycle management strategy for pharmaceutical companies developing drugs that target the immune system.
– Biosimilars are expected to change the landscape for axSpA and will create pricing pressure in the market.

Scope

– Overview of axial spondyloarthritis (axSpA), including etiology, pathophysiology, symptoms, and current treatment recommendations.
– Annualized axSpA market revenue, annual cost of therapy and treatment usage pattern data from 2014 and forecast for ten years to 2024, segmented by ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA).
– Key topics covered include strategic competitor assessment, market characterization, unmet needs, R&D strategies, clinical trial design, and implications for the axSpA market for branded drugs and biosimilars.
– Pipeline analysis: comprehensive data split across different phases and emerging trends, specifically Novartis’s IL-17 inhibitor, Cosentyx; J&J’s IL-12/IL-23 inhibitor, Stelara; Celgene’s novel PDE4 inhibitor, Otezla; and biosimilars.
– Analysis of the current and future market competition in the global axSpA market. Clinical and commercial benchmarking of promising pipeline products versus standard of care treatments and competitive assessment of all therapies for both AS and nr-axSpA . Insightful review of the key industry drivers, restraints and challenges.

Reasons to buy

– Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
– Develop business strategies by understanding the trends shaping and driving the axSpA market.
– Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global axSpA market in the future.
– Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
– Identify emerging players with potentially strong product po
.....


【日本語概要(※自動翻訳出力)】

※以下は、Microsoft社の翻訳システムを使用した自動翻訳結果です。レイアウト崩れと不自然な日本語表現が多く表示されます。

。。。(後略)

【レポートの目次(一部)】

1 Table of Contents
1 Table of Contents 9
1.1 List of Tables 14
1.2 List of Figures 17
2 Introduction 18
2.1 Catalyst 18
2.2 Related Reports 19
2.3 Upcoming Related Reports 19
3 Disease Overview 20
3.1 Etiology and Pathophysiology 20
3.1.1 Etiology 20
3.1.2 Pathophysiology 21
3.2 Symptoms 22
3.2.1 Ankylosing Spondylitis 22
3.2.2 Non-radiographic Axial Spondyloarthritis 24
4 Epidemiology 25
4.1 Risk Factors and Comorbidities 27
4.2 Global Trends 28
4.2.1 US 31
4.2.2 5EU 31
4.2.3 Japan 32
4.3 Forecast Methodology 32
4.3.1 Sources Used for Diagnosed Prevalence of AS 35
4.3.2 Sources Used for Diagnosed Prevalence of Nr-axSpA 38
4.3.3 Sources Used for the Prevalence of HLA-B27 Seropositivity in Diagnosed AS 39
4.3.4 Sources Not Used 40
4.3.5 Forecast Assumptions and Methods, Diagnosed Prevalent Cases of AS — Base Scenario 41
4.3.6 Forecast Assumptions and Methods, Diagnosed Prevalent Cases of Nr-axSpA — Base Scenario 43
4.3.7 Forecast Assumptions and Methods, HLA-B27 Seropositivity in Diagnosed AS 45
4.3.8 Forecast Assumptions and Methods, Diagnosed Prevalent Cases of AS — Alternative Scenario 45
4.3.9 Forecast Assumptions and Methods, Diagnosed Prevalent Cases of Nr-axSpA — Alternative Scenario 46
4.4 Epidemiological Forecast for AS (2014-2024) — Base Scenario 46
4.4.1 Diagnosed Prevalent Cases of AS 46
4.4.2 Age-Specific Diagnosed Prevalent Cases of Ankylosing Spondylitis 48
4.4.3 Sex-Specific Diagnosed Prevalent Cases of AS 49
4.4.4 Age-Standardized Diagnosed Prevalence of AS 51
4.4.5 Diagnosed Prevalent Cases of Nr-axSpA 52
4.4.6 Prevalent Cases of HLA-B27 Seropositivity in Diagnosed AS Cases 54
4.5 Epidemiological Forecast for AS (2014-2024) — Alternative Scenario 57
4.5.1 Diagnosed Prevalent Cases of AS 57
4.5.2 Diagnosed Prevalent Cases of Nr-axSpA 58
4.6 Discussion 60
4.6.1 Epidemiological Forecast Insight 60
4.6.2 Limitations of the Analysis 61
4.6.3 Strengths of the Analysis 61
5 Current Treatment Options 63
5.1 Overview 63
5.2 Product Profiles — Major Brands 65
5.2.1 Enbrel (etanercept) 65
5.2.2 Humira (adalimumab) 69
5.2.3 Remicade (infliximab) 73
5.2.4 Simponi (golimumab) 77
5.2.5 Cimzia (certolizumab pegol) 82
5.2.6 NSAIDs 86
5.2.7 Biosimilars 92
5.2.8 Other Therapies 99
6 Unmet Needs Assessment and Oppportunity Analysis 100
6.1 Overview 100
6.2 Lack of Awareness 101
6.2.1 Unmet Need 101
6.2.2 Gap Analysis 103
6.2.3 Opportunity 105
6.3 Standardization of Diagnosis and Early Treatment 105
6.3.1 Unmet Need 105
6.3.2 Gap Analysis 107
6.3.3 Opportunity 108
6.4 Drugs With Novel MOAs 109
6.4.1 Unmet Need 109
6.4.2 Gap Analysis 110
6.4.3 Opportunity 111
6.5 Recognition of Nr-axSpA 111
6.5.1 Unmet Need 111
6.5.2 Gap Analysis 113
6.5.3 Opportunity 114
7 R&D Strategies 115
7.1 Overview 115
7.1.1 Life-Cycle Management Strategies: Expansion from Key Autoimmune Indications 115
7.1.2 Life-Cycle Management Strategies: Expansion into Nr-axSpA 117
7.1.3 Development of New Formulations and Drug Delivery Methods 118
7.2 Clinical Trial Design 119
7.2.1 Ankylosing Spondylitis 119
7.2.2 Non-radiographic Axial Spondyloarthritis 123
7.2.3 Future Clinical Trials 124
8 Pipeline Assessment 126
8.1 Overview 126
8.2 Promising Drugs in Clinical Development 126
8.2.1 Cosentyx (Secukinumab) 126
8.2.2 Stelara (ustekinumab) 134
8.2.3 Otezla (apremilast) 140
8.3 Additional Drugs in Development for AS 145
9 Pipeline Valuation Analysis 149
9.1 Clinical Benchmarking of Key Pipeline Drugs 149
9.2 Commercial Benchmark of Key Pipeline Drugs 150
9.3 Competitive Assessment 152
9.4 Top Line Ten Year Forecast 154
9.4.1 US 160
9.4.2 5EU 162
9.4.3 Japan 163
10 Appendix 164
10.1 Abbreviations 164
10.2 Bibliography 168
10.3 Methodology 185
10.4 Forecasting Methodology 185
10.4.1 Diagnosed Patients 185
10.4.2 Percent Drug-Treated Patients 186
10.4.3 Drugs Included in Each Therapeutic Class 186
10.4.4 Launch and Patent Expiry Dates 187
10.4.5 General Pricing Assumptions 187
10.4.6 Individual Drug Assumptions 189
10.4.7 Generic Erosion 193
10.4.8 Pricing of Pipeline agents 193
10.5 Physicians and Specialists Included in this Study 194
10.6 Primary Research – Prescriber Survey 195
10.7 About the Authors 196
10.7.1 Author 196
10.7.2 Therapy Area Director 196
10.7.3 Epidemiologist 197
10.7.4 Global Head of Healthcare 197
10.8 About GlobalData 1
.....


【日本語目次(※自動翻訳出力)】

※以下は、Microsoft社の翻訳システムを使用した自動翻訳結果です。レイアウト崩れと不自然な日本語表現が多く表示されます。

。。。(後略)

【レポート販売概要】

■ タイトル:脊椎関節炎治療薬の世界市場機会分析
■ 英文:OpportunityAnalyzer: Axial Spondyloarthritis - Opportunity Analysis and Forecast to 2024 - Event-Driven Update
■ 発行日:2015年7月13日
■ 調査会社:GlobalData
■ 商品コード:GDHC012EPOA
■ 調査対象地域:グローバル

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼
脊椎関節炎治療薬の世界市場機会分析 (OpportunityAnalyzer: Axial Spondyloarthritis - Opportunity Analysis and Forecast to 2024 - Event-Driven Update / GDHC012EPOA)

  • 世界のADHD(注意欠陥・多動性障害)治療薬市場
    ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations Summary GBI Research has released the pharma report, “ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations” Changes in diagnostic criteria have reduced the symptom threshold for d …
  • アジアの手術室用装置市場見通し(~2021)
    Asia-Pacific Operating Room Equipment Market Outlook to 2021 Summary GlobalData’s new report, "Asia-Pacific Operating Room Equipment Market Outlook to 2021", provides key market data on the Asia-Pacific Operating Room Equipment market. The report provides value, in millions of US dollars, volume (in units) and average price data (in US dollars), within market segments - Operating Room Tables, Oper …
  • ドキュメント管理アウトソーシングの世界市場2016-2020
    About the Document Outsourcing Market In the era of digitalization and information economy, organizations adopt IT solutions for the effective management of large volumes of unorganized enterprise documents. Document management solutions are designed to manage routine files and paper-based documents through digital ECM systems. organizations require quick access to enterprise files and information …
  • 走査型電子顕微鏡(SEM)の世界市場2016-2020
    About Scanning Electron Microscope The capacity of an optical microscope is limited by the wavelength of the light used to see the object. When it comes to studying the structure and arrangement of atoms and molecules, optical microscopes fall short because their resolution is limited by the wavelength of light. In 1931, Max Knoll and Ernst Ruska invented the electron microscope. They used electro …
  • グライコミクス/糖鎖生物学の世界市場分析:製品別(酵素、キット、試薬、機器)、用途別(創薬および開発、診断)、エンドユーザー別、セグメント予測、2014-2025
    The global glycomics/glycobiology market is expected to reach USD 2.1 billion by 2025, according to a new report by Grand View Research, Inc. Increasing investment in R&D by research institutes and pharmaceutical & biotechnology companies has been a major factor driving market growth. In addition, technological advancement has led to increased demand for advanced glycomics products for drug discov …
  • ビックデータ分野のリーディング企業分析:Mu Sigma
    Big Data represents a collection of data sets so large and complex that it becomes difficult to process using on-hand database management tool. It is also unstructured, meaning that it is not tabulated, correlated, etc. (e.g. it does not have a pre-defined data model or is not organized in a pre-defined manner). Big Data technologies enable organizations to handle huge datasets and generate inform …
  • がん免疫調節剤の世界市場およびパイプラインインサイト
    Immune system has developed myriad of techniques for preventing progression and proliferation of infectious diseases in the body. Different immunocytes vary in qualitative/quantitative interaction with different components due to which variable immune reactions are produced. The intensity of these interactions could be modified with the help of immunomodulators. They could be natural occurring or …
  • 世界のSCARAロボット市場動向(2012-2016)
    TechNavio’s analysts forecast the Global SCARA Robot market to grow at a CAGR of 4.15 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increased adoption in the assembly process. The Global SCARA Robot market has also been witnessing the emergence of next-generation SCARA robots. However the increasing threat of cross industry vendors could pose a …
  • 繊維セメントの世界市場2015-2022
    According to Stratistics MRC, the Global Fiber Cement market is estimated at $13.15 billion in 2015 and is expected to grow at a CAGR of 5.56% to reach $19.2 billion by 2022. The factors such as hasty increase in construction industries & other infrastructures, conventions against the use of Asbestos and fiber cement having advantages over alternatives are some of the drivers fueling the market gr …
  • 世界の心血管モニタリング装置開発動向:医療機器パイプライン分析2015
    Cardiovascular Monitoring Devices - Medical Devices Pipeline Assessment, 2015 Summary GlobalData's Medical Devices sector report, “Cardiovascular Monitoring Devices - Medical Devices Pipeline Assessment, 2015" provides an overview of Cardiovascular Monitoring Devices currently in pipeline stage. The report provides comprehensive information on the pipeline products with comparative analysis of the …
  • 欧州の産業用ロボット市場2016-2020
    About Industrial Robotics Industrial robots consist of a robotic arm, control cabinet, control panel, and other peripherals. They are used for welding, painting, pick and place, palletizing, cutting, assembly, and product testing, and inspection. These robots are often used to perform tasks that are repetitive, laborious, and dangerous. Technavio’s analysts forecast the European industrial robotic …
  • 高性能合金の世界市場:高融点金属合金、非鉄合金、超合金、白金族合金
    According to Stratistics MRC, the high performance alloys market is estimated at $7.51 billion in 2015 and is projected to reach $10.73 billion by 2022 growing at a CAGR of 5.22% from 2015 to 2022. Increasing demand from aerospace and automotive industry, rising demand for value-added products and rapid growth in emerging regions are some of the factors driving the market growth. Furthermore, tech …
  • チェーンソーの世界市場2015 -2019
    About chainsaws The global population is growing at a steady rate. It is estimated that by 2050, the global population will reach more than 9 billion. This growth in population will lead to rise in demand for land, which will lead to deforestation. The demand for wood for houses, furniture, fuel, pulp, and other needs will also increase simultaneously. This, in turn, will increase the demand for f …
  • 可視光通信(VLC)の世界市場2015-2019
    Technavio expects the global visible light communication (VLC) market to grow at a very optimistic rate, posting a CAGR of almost 64% during the forecast period. Visible light communication is a wireless technology that uses light emanated by LED bulbs to provide a network for high-speed communication parallel to Wi-Fi. This technology is a faster and cheaper optical version of Wi-Fi. The market g …
  • 心臓カテーテル(医療機器)のグローバル新興国市場(2012-2018)
    BRICSS Cardiac Catheters market value is expected to reach US$1.7 billion by 2016, primarily supported by the product types - Electrophysiology (EP) Catheters, PTA Balloon Catheters, Guiding Catheters and ….etc. China accounts for nearly 27% of the market share and India claims more than 25%. In terms of CAGR, China is the fastest growing region while India and South Korea are just behind. Among t …
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。